查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088896

骨質疏鬆症治療和骨折癒合市場：依療法、給藥途徑、骨折類型和最終用戶分類－2026-2032年全球市場預測

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, Fracture Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗骨質疏鬆治療和骨折癒合市場將成長至 293.5 億美元，複合年成長率為 8.77%。

主要市場統計數據
基準年 2025 162.8億美元
預計年份：2026年 177.2億美元
預測年份 2032 293.5億美元
複合年成長率 (%) 8.77%

隨著人口老化和骨折後治療費用的增加，骨質疏鬆症和脆性骨折仍然是公共衛生和商業領域面臨的重大挑戰。根據國際骨質疏鬆症基金會統計，全球有超過2億人患有骨質疏鬆症，估計50歲以上的女性中，三分之一、男性中，五分之一的人一生中會發生骨質疏鬆性骨折。髖部、脊椎和腕部骨折是具有重要臨床意義的問題，因為它們常常導致老年人活動能力喪失、骨折復發、需要入住養老機構，並增加死亡風險。

抗骨質疏鬆治療和骨折癒合策略不再侷限於單純提高骨骼密度。目前的治療方案擴大結合骨折風險評估、雙能量X光檢測法（DXA）、降低跌倒風險、最佳化鈣和維生素D攝取、使用抗吸收藥物（如雙磷酸鹽和地Denosumab）以及促進骨形成的藥物（如特立帕肽、阿巴洛帕肽和羅莫索單抗），尤其針對骨折風險極高的患者。對於業界領導者而言，成長的關鍵在於證明其能夠顯著降低骨折發生率、保證治療的連續性、進行安全監測、體現保險報銷價值，以及將其整合到骨折後二級預防項目中。

抗骨質疏鬆症治療前景的變革性變化

抗骨質疏鬆症治療格局正因日益重視二級骨折預防、前驅骨折後的早期療育以及基於絕對骨折風險的患者分層而發生重塑。證據表明，許多脆性骨折患者未接受骨質疏鬆症的評估或治療，促使一些成熟的醫療保健系統擴大了骨折聯絡服務。彌合這一治療缺口如今已成為臨床和市場進入方面的一項重要優先事項。

人工智慧對骨骼健康的累積影響

人工智慧 (AI) 的影響力正在穩步擴大，其應用領域涵蓋骨質疏鬆症檢測、骨折風險預測、臨床工作流程最佳化以及真實世界證據生成等。 AI 驅動的影像工具可以輔助進行常規的電腦斷層掃描機械篩檢、識別X光相片上的椎體骨折，並為可能漏診的患者提供骨骼健康狀況的自動預警。這些應用尤其重要，因為椎體骨折雖然是未來骨折的強烈預測指標，卻常被忽略。

抗骨質疏鬆治療的關鍵區域見解

隨著中國、印度、日本、韓國和澳洲面臨人口快速老化和骨折負擔日益加重的困境，亞太地區正成為重要的成長區域。日本是世界上老化程度最高的國家之一，擁有成熟的骨質疏鬆症治療體系；而中國和印度雖然擁有龐大的患者群體，但仍面臨著診斷不足、雙能X線吸收法（DXA）檢測機會不均以及經濟負擔等挑戰。澳洲和韓國在基於指南的篩檢和骨折後護理方面取得了進展，為能夠提高風險識別率和治療依從性的療法和數位化工具創造了市場機會。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協市場，由於都市化、預期壽命延長以及私人醫療保健體系的擴張，對骨骼健康診斷和藥物治療的需求不斷成長，使其具有重要的戰略意義。海灣合作理事會（GCC）地區醫療保健領域的巨額投資、完善的專科醫院網路以及公認的嚴重維生素D缺乏症問題，使其成為綜合骨折預防計畫和高階治療的理想市場。歐盟透過其集中化的監管流程、對藥物安全監測的期望、療效比較要求以及國家醫保報銷審查，持續影響全球標準。

對主要骨質疏鬆症市場關鍵國家的洞察

美國仍然是最重要的商業性市場之一，這得益於臨床指南、符合條件的患者可享受的聯邦醫療保險（Medicare）骨骼密度檢測報銷以及品牌藥和學名藥的高使用率。然而，脆性骨折後的治療率仍然很低。加拿大強調實證處方和協作醫療，而墨西哥和巴西由於人口老化和對私人醫療保健投資的增加，需求也在成長，但診斷率和獲得專科治療的機會差異很大。

為行業領導者提供的實用建議

產業領導者應優先考慮那些能夠降低骨折風險、提高用藥依從性並能無縫融入骨折後臨床工作流程的療法和服務。 「優先使用合成代謝藥物」策略（針對極高風險患者）、Denosumab轉換方案、腎臟安全方案以及患者支持項目，都需要有明確的治療效果和持續性證據支持。

調查方法

本執行摘要基於系統性的檢驗方法，該方法結合了同行評審的臨床文獻、骨質疏鬆症治療指南、監管文件、公共衛生資料集以及來自國際骨質疏鬆症基金會 (IOF)、世界衛生組織相關資源、國家衛生機構和主要醫學調查方法等權威機構的已驗證流行病學文獻。證據的評估是基於其與抗骨質疏鬆療法、骨折癒合、骨折預防以及真實臨床實踐中的治療路徑的臨床相關性。

結論

抗骨質疏鬆治療和骨折癒合正邁入一個更一體化的時代，融合了骨折預防、骨折後介入、人工智慧輔助檢測和個人化治療方案。儘管強勁的人口需求和大量未接受治療的患者推動了市場成長，但其發展仍取決於診斷水平的提高、藥物依從性的改善、安全管理的完善以及保險公司對其價值的認可。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗骨質疏鬆治療與骨折癒合市場：依治療類型分類

  • 雙磷酸鹽類藥物
    • 阿崙膦酸鈉
    • Ibandronate sodium
    • 利塞膦酸鈉
    • Zoledronic acid
  • 荷爾蒙補充療法
    • 聯合荷爾蒙療法
    • 雌激素療法
  • 單株抗體
    • Denosumab
      • 普羅利亞
      • Xgeva
    • 羅莫索單抗
  • 副甲狀腺素類似物
    • 阿巴洛帕拉肽
    • 特立帕肽
  • 選擇性雌激素受體調節
    • Bazedoxifene
    • Raloxifene

第8章：抗骨質疏鬆治療與骨折癒合市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第9章：抗骨質疏鬆治療與骨折癒合市場：依骨折類型分類

  • 髖關節
  • 脊椎
  • 手腕

第10章：抗骨質疏鬆治療與骨折癒合市場：依最終使用者分類

  • 居家照護
  • 醫院
  • 專科診所

第11章：抗骨質疏鬆治療與骨折癒合市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：抗骨質疏鬆治療與骨折癒合市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：抗骨質疏鬆治療與骨折癒合市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Healthy Life Pharma Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Sanofi SA
  • Taj Pharmaceuticals
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market is projected to grow by USD 29.35 billion at a CAGR of 8.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.28 billion
Estimated Year [2026] USD 17.72 billion
Forecast Year [2032] USD 29.35 billion
CAGR (%) 8.77%

Osteoporosis and fragility fractures remain a high-burden public health and commercial priority as populations age and post-fracture care costs rise. The International Osteoporosis Foundation reports that osteoporosis affects more than 200 million people worldwide, while one in three women and one in five men over age 50 are expected to experience an osteoporotic fracture during their lifetime. These fractures are clinically significant because hip, vertebral, and wrist fractures often trigger loss of mobility, repeat fractures, institutional care, and elevated mortality risk in older adults.

Anti-osteoporosis therapy and fracture healing strategies are moving beyond bone mineral density improvement alone. Current care pathways increasingly combine fracture risk assessment, dual-energy X-ray absorptiometry, fall-risk reduction, calcium and vitamin D optimization, antiresorptive drugs such as bisphosphonates and denosumab, and anabolic agents such as teriparatide, abaloparatide, and romosozumab for patients at very high fracture risk. For industry leaders, growth depends on demonstrating clinically meaningful fracture reduction, treatment persistence, safety monitoring, reimbursement value, and integration into post-fracture secondary prevention programs.

Transformative Shifts in the Osteoporosis Care Landscape

The osteoporosis treatment landscape is being reshaped by a stronger focus on secondary fracture prevention, early intervention after sentinel fractures, and patient stratification by absolute fracture risk. Fracture liaison services are expanding in several mature health systems because evidence shows that many patients who sustain fragility fractures do not receive osteoporosis evaluation or therapy. Closing this treatment gap is now a major clinical and market access priority.

Therapeutic sequencing is also changing. Long-term bisphosphonate use remains central due to proven fracture reduction and broad availability, but very-high-risk patients are increasingly considered for anabolic-first or anabolic-to-antiresorptive strategies to rapidly build bone and maintain gains. At the same time, real-world adherence, rare adverse events, renal limitations, injection burden, and discontinuation-related rebound fracture risk with denosumab are influencing prescribing decisions and product differentiation.

Cumulative Impact of Artificial Intelligence on Bone Health

Artificial intelligence is accumulating impact across osteoporosis detection, fracture-risk prediction, clinical workflow prioritization, and real-world evidence generation. AI-enabled imaging tools can support opportunistic screening from routine CT scans, vertebral fracture identification on radiographs, and automated bone health alerts for patients who might otherwise remain undiagnosed. These applications are especially relevant because vertebral fractures are frequently under-recognized despite being strong predictors of future fractures.

AI is also improving trial design and commercialization. Machine learning can help identify high-risk cohorts, model treatment persistence, detect safety signals in claims and electronic health record datasets, and personalize outreach for patients after a fracture. However, adoption depends on transparent validation, bias testing across sex and ethnicity, interoperability with hospital systems, and regulatory-grade clinical evidence demonstrating that AI improves outcomes rather than simply adding alerts.

Key Regional Insights for Osteoporosis Therapy

Asia-Pacific is becoming a pivotal growth region as China, India, Japan, South Korea, and Australia face rapid population aging and rising fracture burden. Japan has one of the world's oldest populations and a mature osteoporosis treatment environment, while China and India offer large patient pools but continue to face underdiagnosis, uneven DXA access, and affordability constraints. Australia and South Korea are advancing guideline-based screening and post-fracture care, creating opportunities for therapies and digital tools that improve risk detection and adherence.

North America remains a high-value market due to established reimbursement systems, specialist networks, clinical guideline adoption, and broad use of DXA and fracture-risk assessment. Latin America, led by Brazil and Mexico, shows growing demand but faces gaps in screening infrastructure and access to advanced biologic therapies. Europe benefits from national fracture prevention programs, health technology assessment discipline, and strong academic research, while the Middle East is shaped by high vitamin D deficiency prevalence, diabetes burden, and expanding specialty care. Africa remains underpenetrated, with limited DXA capacity and fragmented access, but urban aging and noncommunicable disease growth are increasing the need for scalable osteoporosis screening and treatment models.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining strategic importance as urbanization, longer life expectancy, and expanding private healthcare systems increase demand for bone health diagnostics and pharmacologic treatment. The GCC is characterized by high healthcare investment, specialist hospital development, and a recognized burden of vitamin D deficiency, making it attractive for integrated fracture prevention programs and premium therapies. The European Union continues to influence global standards through centralized regulatory pathways, pharmacovigilance expectations, comparative effectiveness requirements, and national reimbursement reviews.

BRICS economies combine large patient populations, local manufacturing scale, and increasing clinical trial participation, although access remains uneven across income groups and public insurance systems. G7 markets lead in innovation, real-world evidence adoption, AI-enabled diagnostics, and advanced biologic use, but they also impose rigorous cost-effectiveness expectations. NATO-aligned markets add relevance from a supply-chain resilience perspective, as continuity of sterile injectables, biologics, active pharmaceutical ingredients, and orthopedic trauma care has become a higher priority after recent global disruptions.

Key Country Insights in Major Osteoporosis Markets

The United States remains one of the most commercially significant markets, supported by clinical guidelines, Medicare coverage for bone density testing in eligible patients, and high use of branded and generic therapies; however, treatment rates after fragility fracture remain a persistent gap. Canada emphasizes evidence-based prescribing and coordinated care, while Mexico and Brazil show rising demand as aging populations and private healthcare investment increase, though diagnosis rates and access to specialty therapy vary widely.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national reimbursement systems, fracture liaison service adoption, and health technology assessment scrutiny. Russia has a sizable aging population and demand for cost-effective antiresorptives, but access can differ regionally. In Asia-Pacific, China and India represent scale and long-term growth potential, Japan provides a mature market with strong geriatric demand, South Korea is advancing digital healthcare integration, and Australia benefits from guideline-driven osteoporosis management and structured post-fracture care initiatives.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and services that prove fracture reduction, improve adherence, and fit seamlessly into post-fracture clinical workflows. Anabolic-first strategies for very-high-risk patients, denosumab transition planning, renal-safe options, and patient support programs should be positioned with clear evidence on outcomes and persistence.

Organizations should also invest in partnerships with fracture liaison services, orthopedic networks, radiology groups, and digital health vendors to capture patients at the point of fracture or incidental imaging. Market access teams should build region-specific value dossiers using real-world evidence, cost-offset models for avoided hip fractures, and clear safety-management protocols to support payer confidence.

Research Methodology

This executive summary is grounded in a structured research methodology combining peer-reviewed clinical literature, osteoporosis treatment guidelines, regulatory documents, public health datasets, and validated epidemiological references from recognized organizations such as the International Osteoporosis Foundation, WHO-linked resources, national health agencies, and major medical societies. Evidence was screened for clinical relevance to anti-osteoporosis therapy, fracture healing, fracture prevention, and real-world treatment pathways.

The analysis further applies market triangulation across epidemiology, reimbursement context, product class dynamics, guideline adoption, and regional healthcare infrastructure. Insights were validated for consistency with current clinical standards, including the established role of antiresorptive therapies, the use of anabolic therapies in high-risk populations, and the growing role of AI-enabled imaging and risk stratification.

Conclusion

Anti-osteoporosis therapy and fracture healing are entering a more integrated era in which fracture prevention, post-fracture intervention, AI-enabled detection, and personalized treatment sequencing are converging. The market is supported by strong demographic demand and a substantial untreated patient population, but growth will depend on improving diagnosis, adherence, safety management, and payer-recognized value.

Organizations that combine evidence-backed therapies with digital screening, real-world outcome tracking, and scalable fracture liaison partnerships will be best positioned to capture growth. The strongest competitive advantage will come from converting osteoporosis care from episodic prescription activity into a coordinated, data-driven fracture prevention ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type

  • 7.1. Bisphosphonates
    • 7.1.1. Alendronate
    • 7.1.2. Ibandronate
    • 7.1.3. Risedronate
    • 7.1.4. Zoledronic Acid
  • 7.2. Hormone Replacement Therapy
    • 7.2.1. Combined Hormone Therapy
    • 7.2.2. Estrogen Therapy
  • 7.3. Monoclonal Antibodies
    • 7.3.1. Denosumab
      • 7.3.1.1. Prolia
      • 7.3.1.2. Xgeva
    • 7.3.2. Romosozumab
  • 7.4. Parathyroid Hormone Analogues
    • 7.4.1. Abaloparatide
    • 7.4.2. Teriparatide
  • 7.5. Selective Estrogen Receptor Modulators
    • 7.5.1. Bazedoxifene
    • 7.5.2. Raloxifene

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral

9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type

  • 9.1. Hip
  • 9.2. Spinal
  • 9.3. Wrist

10. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Anti-Osteoporosis Therapy & Fracture Healing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Anti-Osteoporosis Therapy & Fracture Healing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Anti-Osteoporosis Therapy & Fracture Healing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Amgen Inc.
  • 15.2. Eli Lilly and Company
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. GSK plc
  • 15.5. Healthy Life Pharma Pvt. Ltd.
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Manus Aktteva Biopharma LLP
  • 15.8. Merck & Co., Inc.
  • 15.9. Novartis AG
  • 15.10. Pfizer Inc.
  • 15.11. Salvavidas Pharmaceutical Private Limited
  • 15.12. Sanofi S.A.
  • 15.13. Taj Pharmaceuticals
  • 15.14. Taj Pharmaceuticals Limited
  • 15.15. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BISPHOSPHONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BISPHOSPHONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BISPHOSPHONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALENDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALENDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALENDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IBANDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IBANDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IBANDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RISEDRONATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RISEDRONATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RISEDRONATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ZOLEDRONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HORMONE REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMBINED HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DENOSUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DENOSUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DENOSUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROLIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROLIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROLIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL XGEVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL XGEVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL XGEVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ROMOSOZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ROMOSOZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ROMOSOZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARATHYROID HORMONE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ABALOPARATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ABALOPARATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ABALOPARATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TERIPARATIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TERIPARATIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TERIPARATIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SELECTIVE ESTROGEN RECEPTOR MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BAZEDOXIFENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BAZEDOXIFENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BAZEDOXIFENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RALOXIFENE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RALOXIFENE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RALOXIFENE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SPINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL WRIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL WRIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL WRIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE,